1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Skin And Soft Tissue Infections - Pipeline Review, H2 2014

Skin And Soft Tissue Infections - Pipeline Review, H2 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 72 pages

Skin And Soft Tissue Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Skin And Soft Tissue Infections - Pipeline Review, H2 2014’, provides an overview of the Skin And Soft Tissue Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Skin And Soft Tissue Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Skin And Soft Tissue Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Skin And Soft Tissue Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Skin And Soft Tissue Infections - Pipeline Review, H2 2014
Table of Contents

Introduction 6
Global Markets Direct Report Coverage 6
Skin and Soft Tissue Infections Overview 7
Therapeutics Development 8
Pipeline Products for Skin And Soft Tissue Infections - Overview 8
Pipeline Products for Skin And Soft Tissue Infections - Comparative Analysis 9
Skin And Soft Tissue Infections - Therapeutics under Development by Companies 10
Skin And Soft Tissue Infections - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Skin And Soft Tissue Infections - Products under Development by Companies 14
Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development 15
Atox Bio Inc. 15
Cubist Pharmaceuticals, Inc. 16
Dong-A Socio Group 17
Durata Therapeutics, Inc. 18
Melinta Therapeutics, Inc 19
Takeda Pharmaceutical Company Limited 20
Wockhardt Limited 21
Skin And Soft Tissue Infections - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AB-103 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
ceftaroline fosamil - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
dalbavancin - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
KBP-7072 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
RX-04 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Small Molecules for SSTI and CAP Infections - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
tedizolid phosphate - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
tedizolid phosphate - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
VAL-301 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
WCK-2349 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Skin And Soft Tissue Infections - Recent Pipeline Updates 46
Skin And Soft Tissue Infections - Dormant Projects 63
Skin And Soft Tissue Infections - Product Development Milestones 64
Featured News and Press Releases 64
Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority 64
Sep 03, 2014: Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 64
Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections 65
Aug 05, 2014: Cubist's Once-daily SIVEXTRO (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations 65
Mar 31, 2014: FDA Advisory Committee Unanimously Recommends Approval of Cubist's SIVEXTRO (Tedizolid Phosphate) as Treatment for Serious Skin Infections 66
Feb 27, 2014: Cubist Announces EMA Acceptance of Tedizolid Marketing Authorization Application for Review 67
Dec 23, 2013: European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin 68
Dec 03, 2013: Durata Therapeutics Submits Marketing Authorization Application for Dalbavancin 68
Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial 69
Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Tables

Number of Products under Development for Skin And Soft Tissue Infections, H2 2014 8
Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Skin And Soft Tissue Infections - Pipeline by Atox Bio Inc., H2 2014 15
Skin And Soft Tissue Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 16
Skin And Soft Tissue Infections - Pipeline by Dong-A Socio Group, H2 2014 17
Skin And Soft Tissue Infections - Pipeline by Durata Therapeutics, Inc., H2 2014 18
Skin And Soft Tissue Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 19
Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 20
Skin And Soft Tissue Infections - Pipeline by Wockhardt Limited, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Skin And Soft Tissue Infections Therapeutics - Recent Pipeline Updates, H2 2014 46
Skin And Soft Tissue Infections - Dormant Projects, H2 2014 63

List of Figures

Number of Products under Development for Skin And Soft Tissue Infections, H2 2014 8
Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Top 10 Targets, H2 2014 23
Number of Products by Stage and Top 10 Targets, H2 2014 24
Number of Products by Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 26
Number of Products by Top 10 Routes of Administration, H2 2014 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 28
Number of Products by Top 10 Molecule Types, H2 2014 29
Number of Products by Stage and Top 10 Molecule Types, H2 2014 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.